CVS vs OPCH: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CVS and OPCH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CVS and OPCH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CVS Health runs three reporting segments. Health Care Benefits is the Aetna insurance business, which earns premiums from roughly 26 million medical members and profits when claims (the medical benefit ratio) stay below what it collects. Health Services is built around the Caremark pharmacy benefit manager, which negotiates drug prices and manages pharmacy claims for health plans and employers and generated over $48 billion of revenue in Q1 2026. Pharmacy and Consumer Wellness is the familiar retail footprint of CVS drugstores, which makes money filling prescriptions and selling front-of-store health and consumer goods, with same-store prescription volumes up nearly 7% in Q1 2026.

Full CVS guide

Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (like post-hospital antibiotics and nutrition) and chronic conditions (such as immune, neurologic, and inflammatory diseases). It runs a nationwide network of pharmacies and nursing infrastructure, partners with drug manufacturers for distribution, and contracts with payers and health systems, making it the largest standalone player in a fragmented home-infusion market where the top few providers hold roughly a third of share.

Full OPCH guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CVS drivers: Integrated model under one roof; Turnaround and improving Aetna margins.
• OPCH drivers: Acute infusion demand and hospital partnerships; Margin and cost discipline holding profit targets.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. For OPCH, the most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CVS if you believe its drivers more; OPCH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CVS and OPCH guides.

CVS. CVS trades at a low forward earnings multiple versus the broad market, which reflects lingering caution after the 2023 to 2024 Aetna downturn rather than current results. The value angle rests on whether improving margins and ~$400 billion of revenue can support the raised guidance. Figures are approximate and tied to the asOf date; verify live quotes and the latest filings before acting.

OPCH. OPCH trades around the low $20s with a market cap near $3.4 billion, a forward P/E in the low teens that sits well below the broader market and many healthcare-services peers. The discount reflects the flat 2026 revenue outlook and drug-mix headwinds rather than a distressed balance sheet, and trailing free cash flow near $170 million underpins the profile.

Headline figures (approximate, 2026-06-27): CVS shows revenue (annual run-rate) ~$400 billion; FY2026 guidance at least ~$405 billion, adjusted eps (fy2026 guidance) ~$7.30 to $7.50 (Q1 2026 was ~$2.57), aetna medical benefit ratio (q1 2026) ~84.6%, improved from ~87.3% a year earlier, dividend yield ~2.5% (~$2.66 annual, ~$0.665 quarterly); OPCH shows revenue (ttm) ~$5.7B, fy2026 revenue guidance ~$5.68B to $5.78B, adjusted ebitda (fy2026 guide) ~$480M to $505M, adjusted eps (fy2026 guide) ~$1.82 to $1.92.

CVS and OPCH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CVS and OPCH exposure against your real portfolio. It is not an investment adviser.